News | Heart Valve Technology | November 23, 2015

NaviGate Reports First Patient Treated With its Trancatheter Mitral Valve

Patient’s mitral regurgitation improved immediately from 4+ to zero

November 23, 2015 — NaviGate Cardiac Structures Inc. (NCSI) announced that a first-in-human implant of its catheter-guided, mitral-valved stent into a beating heart was performed successfully in a 53-year-old male patient presenting with severe 4+ mitral regurgitation (MR). The interventional team was led by  Cristián Baeza Prieto, M.D., at San Borja Arriarán Hospital in Santiago, Chile, on Oct. 26, 2015. The patient is thriving at four weeks post-procedure. 

Early post-surgical evaluation showed the NCSI catheter-guided procedure significantly improved the patient’s heart function by totally eliminating mitral regurgitation. The NaviGate technology involves the use of a diffuser-shaped or truncated-cone nitinol stent including a tri-leaflet pericardial valvular mechanism that restores mitral valve function in patients with moderate or severe MR and who have been determined to be inoperable or at high risk of mortality if treated by conventional heart surgery. The valve tissue is preserved by the usual fixation but includes technology of dehydration licensed from Cleveland Clinic that removes the toxic fixative and allows shipment of the device in dehydrated form. 

NCSI chose to initially deliver the valve by a transatrial approach, thus minimizing the complications experienced by heart valves presently delivered transapically through a heart tip that is severely damaged by the disease and that must maintain pumping for a lifetime after recovery from the apical puncture. 

The implant procedure was performed by Prieto, who is professor of cardiac surgery at San Borja Arriarán Hospital, as part of a feasibility study that will be also carried out in Krakow, Poland, and Varese, Italy. Assisting Baeza was Gabriel Maluenda, M.D., interventional cardiologist at the institution.

“The patient was considered at very high risk for conventional surgery,” said Baeza. “The implantation was completed and the valve began functioning well upon completion of the procedure. I was able to make minor adjustments to the valve position and see a mitral valve demonstrating normal function. This will be an excellent addition to our armamentarium in the treatment of these patients, who have at present no viable choice to survive this condition.”

Mitral valve disease affects about 2-3 percent of the world's population; an estimated 2.3 million patients in the United States and similar number in Europe suffer from moderate to severe mitral regurgitation. Approximately 500,000 new patients present every year with moderate to severe MR in the United States alone, while over 80 percent are untreated for this disease.  A significant number of patients have limited options for treatment because they are too sick to survive surgery.

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init